Recent Updates
Recently added Catalysts
RADX Positive Sentiment Score: 70/100

Half Year Report and Appendix 4D 31 December 2024

Friday, February 28, 2025 1 min read
Key Takeaway: Radiopharm Theranostics has made significant progress with the initiation of a Phase 1/2a clinical study for BetaBart (RV-01) and received IND approval from the US FDA for a therapeutic study targeting B7H3. The company has also reported positive updates across four of its clinical programs, indicating a strong pipeline and potential for future growth.
Price reaction · baseline $5.52 (2025-02-28T15:12:00.000Z) · hit during market hours · clean, no other RADX news in the window
day 0 close
-9.4%
day 1
-0.4%
day 3 · peak
+38.4%

Market Sentiment Analysis

POSITIVE FACTORS

  • Radiopharm Theranostics has initiated a Phase 1/2a clinical study.
  • IND approval received from the US FDA for a new therapeutic study.
  • Positive clinical updates reported across four programs.

Full Press Release Details

• Announcements
• Periodic Reports , Price Sensitive
• February 28, 2025
Loading Viewer…

More Announcements & Updates

• Announcements
• May 30, 2025
• Announcements
• October 2, 2024
• Announcements
• October 19, 2022
• Announcements
• November 25, 2024

Radiopharm Theranostics Doses First Patient in Phase 1/2a ClinicalStudy of BetaBart (RV-01)

Zacks SCR Analysts Share Their Best Small-Cap Research Ideas for 2026

Radiopharm Theranostics Provides Positive Clinical Updates Across Four Programs

CLINICAL UPDATE AND CAPITAL RAISING OCTOBER 20th, 2025

Radiopharm Theranostics Receives IND approval from US FDA to Initiate Phase I Therapeutic Clinical Study to target B7H3 with Betabart (RV-01)

Dr. Oliver Sartor Appointed to Radiopharm Scientific Advisory Board

• RAD Presentation June 2026
• Zacks Small-Cap Research 2026
• RAD Presentation March 2026
• Radiopharm Theranostics Doses First Patient in Phase 1/2a ClinicalStudy of BetaBart (RV-01)
• Zacks SCR Analysts Share Their Best Small-Cap Research Ideas for 2026
• Zacks Small-Cap Research

Frequently Asked Questions

What is the focus of the Phase 1/2a clinical study?

The Phase 1/2a clinical study focuses on BetaBart (RV-01).

What recent approval did Radiopharm Theranostics receive?

Radiopharm Theranostics received IND approval from the US FDA.

How many clinical programs received positive updates?

Positive updates were reported across four clinical programs.

When was the Half Year Report released?

The Half Year Report was released on February 28, 2025.

Tags: RADX Viatris Investor Conferences Healthcare Radiopharm Theranostics BetaBart Phase 1/2a clinical study B7H3
Last updated: Feb 28, 2025